Shares of Healthcare sector company Cytokinetics moved 5.8% today, and are now trading at a price of $38.08. The mid-cap stock's daily volume was 477,139 compared to its average volume of 1,101,658. The S&P 500 index returned a -0.2% performance.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is based in South San Francisco and has 253 full time employees. Its market capitalization is $3,603,548,672.
13 analysts are following Cytokinetics and have set target prices ranging from $55 to $82 per share. On average, they have given the company a rating of buy. At today's prices, CYTK is trading -44.31% away from its average analyst target price of $68.38 per share.
Over the last year, CYTK shares have gone down by -0.3%, which represents a difference of 15.6% when compared to the S&P 500. The stock's 52 week high is $55.8 per share and its 52 week low is $29.26. Cytokinetics has averaged free cash flows of $-97,283,250.0 over the last four years, with a mean growth rate of -2956.3%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
